StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Seattle Genetics (SGEN) Announces Updated Phase 1 Data for Ladiratuzumab Vedotin (SGN-LIV1A)
December 7, 2017 8:01 AM
Seattle Genetics, Inc. (NASDAQ: SGEN) today announced updated data from an ongoing phase 1 clinical trial evaluating ladiratuzumab vedotin in ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Hot Corp. News
Hot FDA News
Management Comments
Next Articles
Seattle Genetics (SGEN) Reports Five-Year Survival Results from Phase 1 Trial of ADCETRIS (Brentuximab Vedotin) in Frontline Mature T-Cell Lymphoma
December 11, 2017 5:50 AM
Seattle Genetics (SGEN) and Takeda Highlight Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma
December 11, 2017 5:45 AM
Seattle Genetics (SGEN) Presents Updated Analyses from Phase 3 ALCANZA Clinical Trial of ADCETRIS (Brentuximab Vedotin) in CD30-Expressing Cutaneous T-Cell Lymphoma
December 11, 2017 5:39 AM
Seattle Genetics Presents Updated Phase 1 Data for Ladiratuzumab Vedotin (SGN-LIV1A) in Patients with Triple Negative Breast Cancer at 2017 San Antonio Breast Cancer Symposium
December 7, 2017 8:00 AM
